Using pilocarpine hydrochloride eye drops (trade name: Vuity) manufactured by Abbvie Inc. as the reference formulation and pilocarpine hydrochloride eye drops certified by Beijing Fuyuan Pharmaceutical Co., Ltd. as the test formulation, the pharmacokinetic characteristics of a single dose were compared in healthy Chinese subjects. The safety of the reference and test formulations after a single dose in healthy Chinese subjects was evaluated.

Start Date21 Aug 2025

Sponsor / Collaborator

Beijing Foyou Pharma Co., Ltd.

100 Clinical Results associated with Pilocarpine Hydrochloride

100 Translational Medicine associated with Pilocarpine Hydrochloride

100 Patents (Medical) associated with Pilocarpine Hydrochloride

8,226

Literatures (Medical) associated with Pilocarpine Hydrochloride

01 Apr 2026·NEUROCHEMICAL RESEARCH

Analysis of Serum VCAN-AS1 Expression Level in Patients with Cerebral Infarction Secondary Epilepsy and Its Mechanism by Regulating miR-885-3p/NTNG1

Article

Author: Yin, Lida ; Zhang, Meijie ; Meng, Jinhui ; Zhang, Kun ; Li, Yue ; Yin, Xueyong ; Meng, Yanru ; Wang, Liping ; Lin, Yang ; Liu, Zhixin

VCAN-AS1 is a novel long non-coding RNA that participates in diverse disease processes, but the mechanism of its action in cerebral infarction secondary epilepsy (CISE) is unclear. The potential action mechanism of VCAN-AS1 in CISE was explored by this study. VCAN-AS1 and its downstream targets, namely miR-885-3p and Netrin G1 (NTNG1), were screened by the GEO, LncRNASNP2, and miRDB databases. The epileptic mouse and cell models were constructed using pilocarpine and the Mg²⁺-free medium, respectively. ELISA kits or RT-qPCR was used for the measurement of TNF-α/IL-1/IL-6 levels. The levels of Fe²⁺, GSH, and ROS were detected by the specific biochemical kits. GPX4 expression was analyzed by RT-qPCR. Dual-luciferase reporter assay was used to detect the interactions between miR-885-3p and VCAN-AS1 or NTNG1. Meanwhile, the expression levels of VCAN-AS1, miR-885-3p, and NTNG1 were detected by RT-qPCR. Elevated serum levels of VCAN-AS1 were observed in patients with CISE, and silencing of VCAN-AS1 attenuated inflammation and ferroptosis in epilepsy-associated neurons and the hippocampus of epileptic mice. VCAN-AS1 negatively regulated miR-885-3p which subsequently repressed NTNG1 expression. Up-regulation of miR-885-3p inhibited inflammation and ferroptosis in epileptic mouse and cell models, and overexpression of NTNG1 reversed these effects of miR-885-3p. The suppression of VCAN-AS1 expression mitigated neuronal inflammation and ferroptosis in epileptic conditions by targeting the miR-885-3p/NTNG1 regulatory axis, which may be an important molecular mechanism of CISE.

01 Apr 2026·NEUROCHEMICAL RESEARCH

Intranasal Diazepam Outperforms Midazolam and Lorazepam in Early Seizure Control in Pilocarpine-Induced Mice Model

Article

Author: Li, Jiahao ; Zhao, Jiajia ; Wang, Rilla Jiansu ; Zuo, Zhong ; Zhang, Yufeng ; Ban, Weikang ; Tong, Anson Hei-Ka ; Xie, Yuning

Abstract:

Epilepsy is a central nervous system disease characterized by the sudden onset of seizures, loss of consciousness, or confusion. In recent years, many non-intravenous routes of administration of benzodiazepines have been developed for seizure control, with intranasal administration being an attractive route of choice. However, for such a route of administration, there is a lack of evidence on the choice of the epilepsy drug. This study aims to compare the intranasal formulations of three first-line drugs for seizure control, namely midazolam, diazepam, and lorazepam, via an ideal intranasal treatment. A pilocarpine-induced seizure model in mice was used to compare drug efficacy. The three drugs were administered intranasally to 36 C57 mice at a single dose of 1 mg/kg, followed by inducing the seizures via intraperitoneal injection of pilocarpine. The subsequent seizure scores were observed for either 10–100 min. After sacrificing the mice at 10/100 minutes post-dosing, whole brain tissue and plasma were collected to analyze the drug concentrations as well as brain-to-plasma concentration ratios. In addition, effects of these intranasally delivered drugs on neuroinflammation-associated molecules were monitored and compared via the mRNA levels and/or protein expression of GABARα1, TNF-α, and IL-1β in the cortex and hippocampus. Additionally, drug bindings to plasma and brain tissue obtained using the ultrafiltration method were compared, and drug binding affinities towards the GABA A receptor, as determined via the computer docking technique, were also compared. Among the three tested drugs, our results suggested that intranasal diazepam, with the highest brain-to-plasma ratio, was the best in seizure control at 10 min. Although all three drugs showed good stability, similar brain binding and receptor binding affinity, diazepam demonstrated the greatest efficacy in reducing TNF-α mRNA and protein levels, and lowest plasma protein binding, which could contribute to its higher brain-to-plasma ratio and better acute epilepsy control compared to the other two drugs. Our pilot in vivo experiments in the pilocarpine-induced mice seizure model for the first time demonstrated that intranasally administered benzodiazepines are effective for seizure control at the early stage, with intranasally delivered diazepam being the most potent one.

13 Mar 2026·ACS Pharmacology & Translational Science

Ionic Liquid Pilocarpine Serves as Therapeutic Cosolvent and Permeation Enhancer for Glaucoma Medication

Article

Author: Wang, Tzu-Chen ; Mani, Vimalin ; Ates, Burhan ; Trital, Ashish ; Yang, Hu ; Xu, Lei

The efficacy of hydrophobic ocular drugs is significantly hindered by their low bioavailability, for which poor water solubility is a major contributing factor. In this work, we synthesized pilocarpine-derived ionic liquid [Pilo-OEG] Cl (PO) and evaluated its cosolvent properties for the codelivery of the hydrophobic antiglaucoma drug brimonidine (BM) for glaucoma therapy. Pilocarpine was quaternized with 2-[2-(2-chloroethoxy)-ethoxy] ethanol in a one-pot reaction to yield PO, and its structure was confirmed using ¹H NMR and FT-IR spectroscopy methods and further characterized for its rheological property and thermal stability. The HET-CAM assay and cell viability study showed that PO was nonirritating and cytocompatible with trabecular meshwork cells. As a cosolvent, PO increased the solubility of BM and shifted its logP toward hydrophilicity and increased its ex vivo corneal permeability to be 2.7-fold higher. Following topical administration, a single dose of the PO:BM formulation decreased intraocular pressure (IOP) in rats and effectively maintained the IOP reduction for 48 h, whereas the IOP in the rats topically treated with brimonidine tartrate returned to the baseline in less than 12 h. A sustained IOP reduction over 7 days was achieved in a multiple-dose experiment, with efficacy still observed on day 8 by PO: BM. By combining intrinsic muscarinic activity with potent cosolvent properties, PO ionic liquid addresses the solubility and bioavailability challenges of hydrophobic drugs (BM) in a simple formulation (PO:BM), presenting a promising next-generation therapy for the treatment of glaucoma.

109

News (Medical) associated with Pilocarpine Hydrochloride

26 Mar 2026

·allsci.com

MeiraGTx’s AAV2-hAQP1 gene therapy earns FDA breakthrough designation for radiation-induced xerostomia

MeiraGTx Holdings plc (Nasdaq: MGTX), a clinical-stage genetic medicines company headquartered in London and New York, announced that the FDA has granted Breakthrough Therapy Designation for AAV2-hAQP1, an adeno-associated virus serotype 2 vector encoding human aquaporin-1, for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract. The designation adds to the Regenerative Medicine Advanced Therapy (RMAT) designation the FDA had previously granted for the same molecule. MeiraGTx has also separately disclosed that the program has orphan drug designation from FDA for grade 2 and grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy. The Breakthrough Therapy Designation application was supported by three-year data from a Phase I dose escalation study of AAV2-hAQP1 in patients with radiation-induced xerostomia. That study generated data showing improvements in patient-reported xerostomia outcomes and increases in salivary flow after a single administration, with no serious treatment-related adverse events reported. MeiraGTx plans to present full three-year data from all cohorts of the Phase I study at a program update scheduled for April 16, 2026. The company’s Phase II AQUAx2 study (NCT05926765) is currently in final enrollment stages. MeiraGTx has aligned with the FDA on clinical requirements for this study to support a potential Biologics License Application (BLA), with the primary endpoint being change from baseline in the Xerostomia Questionnaire at 12 months following a one-time treatment. The company anticipates data 12 months after the last patient is treated, with a potential BLA filing in the first half of 2027 and a targeted US launch in early 2028. Radiation-induced xerostomia affects patients who have undergone radiotherapy for head and neck cancers, resulting in chronic dry mouth due to salivary gland damage. No approved gene therapies currently exist for this condition. Available treatments are limited to saliva substitutes, sialogogues such as pilocarpine, and supportive care measures, none of which restore salivary gland function at a cellular level. AAV2-hAQP1 is designed to restore fluid secretion by delivering the aquaporin-1 water channel gene directly to remaining salivary gland cells, a mechanistic approach distinct from symptomatic treatments. No other gene therapy candidates for radiation-induced xerostomia appear to be in late-stage clinical development. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 1Gene TherapyOrphan DrugPhase 2Breakthrough Therapy

29 Jan 2026

·firstwordpharma.com

Tenpoint's poised to debut new presbyopia drug after FDA nod, fresh capital

The FDA on Wednesday approved Tenpoint Therapeutics' once-daily presbyopia eye drop Yuvezzi as the company simultaneously closed a $235-million fundraise to support the drug's US launch. The regulatory win also marks Tenpoint's transition from a clinical-stage developer to a commercial ophthalmology company.CEO Henric Bjarke said the new eye drop offers "a new differentiated option for millions of people living with the daily frustration and challenges of presbyopia." The age-related condition affects nearly 128 million people in the US and approximately 2 billion people globally.Yuvezzi (formerly referred to as Brimochol PF) consists of a fixed-dose combination of carbachol and brimonidine tartrate to correct near vision blurriness by modulating pupil size. It becomes at least the fourth prescription eye drop specifically indicated for presbyopia in the last few years. The FDA approved AbbVie's Vuity (pilocarpine ophthalmic solution 1.25%) in 2021 and Orasis Pharmaceuticals' Qlosi (pilocarpine ophthalmic solution 0.4%) two years later. Last August, LENZ Therapeutics joined the pack with an FDA nod for Vizz, a once-daily aceclidine-based eye drop.Tenpoint acquired Yuvezzi through its 2024 buyout of Visus Therapeutics. The filing was supported by Phase III data from the BRIO-I and BRIO-II trials; the first met its primary endpoint for binocular near visual acuity across multiple time points starting at one hour post-administration compared to active controls, while the second showed significant improvement in near vision over control vehicle, with efficacy maintained for up to eight hours.Meanwhile, Tenpoint bolstered its balance sheet by closing an $85-million series B financing led by Janus Henderson, EQT Nexus, Hillhouse and the British Business Bank, alongside a $150-million loan facility with Hercules Capital. The company indicated the funds will be used primarily to support commercialisation, with a launch planned for early in the second quarter.

Phase 3AcquisitionDrug ApprovalClinical Result

28 Jan 2026

·www.biospace.com

/C O R R E C T I O N -- Orasis Pharmaceuticals/

In the news release, NEW DATA DEMONSTRATE QLOSI™ IS PUPIL SELECTIVE WITH CILIARY MUSCLE MOVEMENT NO DIFFERENT THAN A BALANCED SALT SOLUTION (BSS) CONTROL, issued Jan. 27, 2026 by Orasis Pharmaceuticals over PR Newswire, we are advised by the company that the original version contained incorrect information introduced by PR Newswire during transmission. The complete, corrected release follows, with additional details at the end: NEW DATA DEMONSTRATE QLOSI™ IS PUPIL SELECTIVE WITH CILIARY MUSCLE MOVEMENT NO DIFFERENT THAN A BALANCED SALT SOLUTION (BSS) CONTROL In an imaging study from the Bascom Palmer Eye Institute, Qlosi's low-concentration formulation with 0.4% pilocarpine significantly reduced pupil diameter while demonstrating ciliary muscle movement the same as BSS control 1 Findings demonstrate Qlosi is pupil selective, 1 establishing for the first time this unique attribute of low-concentration pilocarpine, and its ability to support presbyopia patients' near vision demands with minimal ciliary muscle response PONTE VEDRA, Fla. , Jan. 27, 2026 /PRNewswire/ -- Orasis Pharmaceuticals, an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities, announced data supporting Qlosi ™ (pilocarpine hydrochloride ophthalmic solution) 0.4% is pupil selective, significantly reducing pupil diameter without a statistically significant change in ciliary muscle response in presbyopic eyes. 1 These data were presented at The Hawaiian Eye & Retina 2026 Conference, held January 17-23 on the Big Island of Hawaii. "The perception of pilocarpine historically has been based on experience with, and research conducted on, higher concentrations of pilocarpine (1% and above). Recently, the notion of a 'pupil selective' mechanism of action (MOA) has been a topic of interest," said Elad Kedar, Chief Executive Office of Orasis Pharmaceuticals . "Qlosi demonstrating minimal ciliary muscle movement, the same as the control tested, is consistent with the results we have seen in real world experience to date—very low rates of adverse events overall without a single serious adverse event reported since launch. We believe this further illustrates why formulation matters and why the concentration-dependent effects demonstrated by Qlosi reinforce how our product was designed with the safety of the presbyopia patient in mind." The prospective, head-to-head clinical study, conducted by the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, evaluated thousands of high-resolution optical coherence tomography (OCT) images to measure how balanced salt solution (BSS), Qlosi (0.4% pilocarpine) and pilocarpine 2%, responded to presbyopia patients' vision demands by looking at ciliary muscle movement, changes in pupil diameter and lens thickness. 1 Ten subjects (mean age 51.5 years, range 46.3–64.3) were enrolled with spherical equivalent −4.00D to +2.00D. 1 Exclusion criteria were prior ocular surgery or comorbidities. 1 The study findings showed Qlosi significantly reduced pupil diameter but produced no significant changes in lens thickness or ciliary muscle response, compared with BSS (p<0.05). 1 Pilocarpine 2% showed a statistically significant change in ciliary muscle movement at near not observed in the BSS and Qlosi groups. 1 "In this study, pilocarpine 0.4% was indistinguishable from the BSS control, while the high‑concentration miotic (pilocarpine 2.0%) triggered statistically significant movement of the ciliary muscle at near, 1 " said Florence Cabot, MD, Assistant Professor of Clinical Ophthalmology, Bascom Palmer Eye Institute, Miami, FL . "These findings are very encouraging, supporting that pilocarpine 0.4% is pupil selective and behaves in a concentration-dependent manner, reinforcing that low-concentration options may be particularly meaningful for patients considering a presbyopia therapy that balances both efficacy and safety." In pivotal Phase 3 clinical trials, Qlosi demonstrated a favorable safety profile, with no serious side effects reported. In real-world use of Qlosi in the first 10 months of launch, there have been no reported cases of retinal detachment, or serious adverse events. 2 About Presbyopia Presbyopia is the loss of ability to focus on near objects as a result of the natural aging process. It occurs mostly after the age of 40 when the crystalline lens of the eye gradually stiffens and loses flexibility. 3 There are almost two billion people globally and more than 128 million people in the U.S. living with presbyopia. 3,4 People with presbyopia experience blurred vision when performing daily tasks that require near visual acuity, such as reading a book, a restaurant menu or messages on a smartphone. Presbyopia cannot be prevented or reversed, and it continues to progress gradually. Many existing treatment options can be either cumbersome or invasive, presenting a significant unmet need for presbyopia patients. Presbyopia can be diagnosed during an eye exam conducted by an eye care professional. 5 About Qlosi Qlosi ™ (pilocarpine hydrochloride ophthalmic solution) 0.4% is a novel, corrective prescription eye drop indicated for the treatment of presbyopia in adults. Qlosi's EyeQ Formulation ™ delivers the lowest effective concentration of pilocarpine approved in a preservative-free eye drop, with a near-neutral pH and dual lubricating agents to provide enhanced safety and patient comfort without compromising on efficacy. 6,7,8 Qlosi improves near visual acuity by pupil modulation, resulting in a "pinhole effect" and an increase in the depth of field, thus increasing the ability to focus on near objects without negatively impacting distance vision. The most commonly reported treatment-related adverse events (TRAEs) were headache and instillation site pain, at rates of 6.8% and 5.8%, respectively. For more information, visit and follow us on Facebook and Instagram . About Orasis Pharmaceuticals Orasis Pharmaceuticals is an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities. Orasis has developed Qlosi ™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel, corrective prescription eye drop for the treatment of presbyopia, or age-related blurry near vision, in adults. Orasis is led by a collaborative team of industry executives and eye care professionals working to transform the standard of care for near vision correction. Orasis is funded by a diverse group of sophisticated and experienced life science and healthcare investors. Orasis has offices in the United States and Israel. For more information, visit or call 1-844-MY-ORASIS and follow us on LinkedIn . Qlosi Indication and Important Safety Information Indication and Usage Qlosi ™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic agonist indicated for the treatment of presbyopia in adults. Important Safety Information CONTRAINDICATIONS Hypersensitivity WARNINGS AND PRECAUTIONS Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination. Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters or vision loss. Qlosi is not recommended to be used when iritis is present. Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the installation of Qlosi and wait 10 minutes before reinsertion. Avoid touching the tip of the vial to the eye or any other surface. ADVERSE REACTIONS The most common adverse reactions (5% to 8%) are instillation site pain and headaches. Please see full Prescribing Information here: qlosi.com/prescribing-information You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Media Contact: MediaInquiries@orasis-pharma.com 412-327-9499 References: 1 Manns F, Cabot F, Ruggeri M. ORASIS–Bascom Palmer Eye Institute Study: Effect of pilocarpine eye drops on ciliary muscle accommodative response; revised analysis by Gerard Smits. Presented at Hawaiian Eye & Retina 2026; January 17-23, 2026; Waikoloa Village, HI. 2 FDA Adverse Event Reporting System (FAERS). Qlosi P. Accessed January 26, 2026. . 3 Holden, B. A., et al. Global Vision Impairment Due to Uncorrected Presbyopia. Arch Ophthalmol. 2008;126(12):1731-1739. . 4 U.S. Census Bureau. United States Census – Populations and People. Accessed January 26, 2026. . 5 WebMD. Presbyopia: Symptoms, diagnosis, and treatment. Accessed January 26, 2026. . 6 U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed January 26, 2026. . 7 Qlosi [package insert]. Ponte Verda, FL. Orasis Pharmaceuticals. 8 Holland E, Karpecki P., Fingeret M., et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther . 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005. Correction: The photo caption in the earlier version was incorrect. View original content to download multimedia: SOURCE Orasis Pharmaceuticals

Clinical ResultPhase 3

100 Deals associated with Pilocarpine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02200	Pilocarpine Hydrochloride	S01EB01 N07AX01	DB01085

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Presbyopia	United States	AbbVie, Inc.	28 Oct 2021
Acute angle-closure glaucoma	United States	Sandoz, Inc.	22 Jun 2010
Sjogren's Syndrome	South Korea	Eisai Korea, Inc.	26 Feb 1998
Glaucoma	South Korea	SAMIL PHARMACEUTICAL Co., Ltd.	01 Feb 1989
Ocular Hypertension	United States	Alcon Laboratories, Inc.	01 Oct 1984
Xerostomia	Canada	Alcon Canada, Inc.	31 Dec 1951

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kerato conjunctivitis sicca	Phase 2	United States	Glaukos Corp.	03 Jan 2022
Xerophthalmia	Phase 2	United States	Glaukos Corp.	-
Miosis	Phase 1	United States	Novus Vision LLC	30 Jan 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05393895 (CTgov)	Phase 3	Presbyopia	178	CSF-1 (CSF-1)	uoozezwtap = lzvkapnewv cpbkxnsvgt (ijsevrscvd, bgwfofyzdv - ebhusawqjk) View more	-	11 Jun 2025
				Vehicle (Vehicle)	uoozezwtap = dhsmcrhmln cpbkxnsvgt (ijsevrscvd, ydiaztdvrt - mbzsitgpvb) View more
NCT04599933 (NEAR-1, CTgov)	Phase 3	Presbyopia	309	CSF-1 (CSF-1)	ikzapftrrc = mzxsyfkswf vutellgntn (slkeynsjrs, kzctpmymyl - rbnatytdqy) View more	-	28 Nov 2023
				Vehicle (Vehicle)	ikzapftrrc = sukozhfupi vutellgntn (slkeynsjrs, qfirchmkja - vvyaeqmqsx) View more
NCT04599972 (NEAR-2, CTgov)	Phase 3	Presbyopia	304	CSF-1 (CSF-1)	ohzowospli = ptbostvlyd vtweoltzig (fdjwncoqas, ggvxvkqqgb - inrcidueng) View more	-	28 Nov 2023
				Vehicle (Vehicle)	ohzowospli = dukfkunmrt vtweoltzig (fdjwncoqas, nirigmvamk - wtdzttwtzg) View more
NCT04675151 (CTgov)	Phase 2	Presbyopia	150	LDP+POS (POS 0.75% First, Then LDP 0.4%)	fjhvzkjkun = hyaviorvmb reyzmqjhod (mhivyrmjqy, mwnvnhfjgk - teuubxbgbl) View more	-	02 Aug 2023
				LDP+POS (POS 0.75% First, Then LDP Vehicle)	fjhvzkjkun = tyxgpkzuav reyzmqjhod (mhivyrmjqy, mzsvopkojr - mctsywutod) View more
GEMINI (ARVO2023)	Phase 3	Presbyopia	750	Pilocarpine HCl ophthalmic solution 1.25%	ficfhmswil(udmtaxiior) = lhjecxyddg rzbjmdotqz (ntfgruhtlx ) View more	-	01 Jun 2023
				Vehicle	ficfhmswil(udmtaxiior) = qkwbyhsyuz rzbjmdotqz (ntfgruhtlx ) View more
NCT03804268 (GEMINI 1, ARVO2023)	Phase 3	Presbyopia	323	Pilocarpine hydrochloride ophthalmic solution 1.25%	ffgelohacq(zdwhbyrjhg) = ygavmbsmya vehqjurvfz (huyhhrhqsb )	-	23 Apr 2023
				Vehicle	ffgelohacq(zdwhbyrjhg) = zekwzrpsoq vehqjurvfz (huyhhrhqsb )
ARVO2023	Phase 2	Presbyopia	150	0.75% Phentolamine Ophthalmic Solution (POS)	yopcoeiptb(edmofowkwd) = dmrkvesbpf jaumnrbxxi (npqvfmbxic )	Positive	23 Apr 2023
				0.4% Low Dose Pilocarpine (LDP)	yopcoeiptb(edmofowkwd) = wdcjprddhw jaumnrbxxi (npqvfmbxic )
NCT04983589 (Virgo, CTgov)	Phase 3	Presbyopia	230	Vehicle (Vehicle)	glhkbcgeiv = xyafysqvgs nhxfrhdmxr (qqjozesrcb, thilewalyx - afiwlrhanr) View more	-	21 Mar 2023
				Pilocarpine HCl (AGN-190584)	glhkbcgeiv = aushzjhjox nhxfrhdmxr (qqjozesrcb, dxvoglpqgj - vdnfxmabbk) View more
NCT05238233 (CTgov)	Phase 4	Anisocoria	11	Reichert phoropter+Proparacaine Hydrochloride+Tropicamide+1% Pilocarpine	xmilsletna = hzfwxyuidq leepcznqto (jhsquyiahw, nhzdqtoile - mxgjqdwykd) View more	-	07 Mar 2023
NCT03885011 (CTgov)	Phase 2	Presbyopia	166	pilocarpine HCl+diclofenac Na (CSF-1-FDC)	apapbuzqdc = ydqysmeion ooixhaacbr (ygwfagkyhk, ekiizsisbh - lwtwdvlqjo) View more	-	26 Jan 2023
				pilocarpine HCl (Pilo)	apapbuzqdc = obrdqqdlra ooixhaacbr (ygwfagkyhk, cuebdyxlvh - tyerpxggds) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis